4D Molecular Therapeutics Inc
(FDMT)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,682 | -107,494 | -80,115 | -54,424 | -26,338 |
| Depreciation Amortization | 634 | 3,462 | 2,679 | 1,923 | 988 |
| Accounts receivable | N/A | 47 | 47 | 47 | 47 |
| Accounts payable and accrued liabilities | -333 | -1,638 | -3,151 | -1,454 | -1,680 |
| Other Working Capital | -4,491 | -1,336 | -978 | -1 | -2,538 |
| Other Operating Activity | 4,966 | 20,274 | 17,047 | 10,455 | 5,971 |
| Operating Cash Flow | $-27,906 | $-86,685 | $-64,471 | $-43,454 | $-23,550 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,012 | -11,536 | -10,443 | -8,479 | -6,413 |
| Purchase Of Investment | -14,729 | -153,313 | -253,821 | -65,879 | -59,694 |
| Sale Of Investment | 58,871 | 147,799 | 282,993 | 77,716 | 11,997 |
| Investing Cash Flow | $43,130 | $-17,050 | $18,729 | $3,358 | $-54,110 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,063 | 3,553 | 1,039 | 939 | 875 |
| Other Financing Activity | -69 | -468 | 0 | -360 | -246 |
| Financing Cash Flow | $10,994 | $3,085 | $1,039 | $579 | $629 |
| Beginning Cash Position | 52,351 | 153,001 | 153,001 | 153,001 | 153,001 |
| End Cash Position | 78,569 | 52,351 | 108,298 | 113,484 | 75,970 |
| Net Cash Flow | $26,218 | $-100,650 | $-44,703 | $-39,517 | $-77,031 |
| Free Cash Flow | |||||
| Operating Cash Flow | -27,906 | -86,685 | -64,471 | -43,454 | -23,550 |
| Capital Expenditure | -1,012 | -11,536 | -10,443 | -8,479 | -6,413 |
| Free Cash Flow | -28,918 | -98,221 | -74,914 | -51,933 | -29,963 |